Tag: Proteostasis Therapeutics (PTI)

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

Proteostasis: Its $100 million agreement with Genentech seems not enough to motivate investors to buy into the stock

Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech about licensing rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network. The agreement does not include cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators and is unrelated to the company’s investigational products or other ongoing research programs in cystic fibrosis. The Proteostasis Network (PN) consists of more than 1,000 proteins organized …
Positive News

Positive News

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-­stage small firm called Proteostasis Therapeutics (PTI) announced positive preliminary results from ongoing Phase 1 cystic fibrosis studies. The trial involved the firm’s proprietary combination therapy doublet, PTI-­808 + PTI-­801...